CD8A and neoplasm: DC101 can decrease the high expression of VEGF after VDA therapy; temporarily normalize tumor blood vessels; increase the number of CD8+ T cells within the tumor; and significantly increase the levels of IFN-γ, TNF-α, and IL-2 after treatment.